Skip to content
Screener

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
-$653M-121%
Amgen logo
AmgenAMGN
$2.77B+76.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$91M
CTO
Citius Oncology, Inc.CTOR
-$26.84M-259%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$80.26M+172%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$749.57M+96.8%
Enterprise value$738.05M+118%
P/S41×+38.3×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%
Debt / equity0.0×
Current ratio9.4×+5.2×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Income (loss) from operations(23,781)(1,286)(43,453)21,336
Interest income3,1571,1784,6472,133
Other income18171128
Income (loss) before income taxes(20,606)(91)(38,795)23,497
Provision for income taxes6063119126
Net income (loss) attributable to common stockholders(20,666)(154)(38,914)23,371
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net of tax(298)34(307)6

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is CytomX Therapeutics's pre-tax income?
CytomX Therapeutics (CTMX) reported pre-tax income of -$20.61M in Q2 2026.
How has CytomX Therapeutics's pre-tax income changed year-over-year?
CytomX Therapeutics's pre-tax income decreased by 22544.0% year-over-year, from -$91K to -$20.61M.
What is the long-term trend for CytomX Therapeutics's pre-tax income?
Over 4 years (2021 to 2025), CytomX Therapeutics's pre-tax income has grown at a -38.0% compound annual growth rate (CAGR), from -$115.87M to -$17.13M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about CytomX Therapeutics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude